300871 回盛生物
已收盘 05-28 15:00:00
资讯
新帖
简况
回盛生物（300871）披露终止向特定对象发行股票审核决定公告，5月25日股价下跌3.38%
证券之星 · 05-25
回盛生物（300871）披露终止向特定对象发行股票审核决定公告，5月25日股价下跌3.38%
回盛生物不超2.5亿定增到期失效 保荐机构为中信建投
中金财经 · 05-25
回盛生物不超2.5亿定增到期失效 保荐机构为中信建投
回盛生物最新公告：深交所终止对公司向特定对象发行股票审核
证券之星 · 05-22
回盛生物最新公告：深交所终止对公司向特定对象发行股票审核
回盛生物(300871.SZ)发布一季度业绩，归母净利润7767.47万元，增长74.56%
智通财经 · 04-27
回盛生物(300871.SZ)发布一季度业绩，归母净利润7767.47万元，增长74.56%
回盛生物(300871)3月31日股东户数2.3万户，较上期增加15.32%
证券之星 · 04-27
回盛生物(300871)3月31日股东户数2.3万户，较上期增加15.32%
回盛生物涨5.81%，西南证券五日前给出“买入”评级
证券之星 · 04-27
回盛生物涨5.81%，西南证券五日前给出“买入”评级
黄果任国家药监局党组书记；全国四成统筹地区已完成上年度清算
21世纪经济报道 · 04-17
黄果任国家药监局党组书记；全国四成统筹地区已完成上年度清算
回盛生物（300871）披露2025年年度报告，4月16日股价上涨1.6%
证券之星 · 04-16
回盛生物（300871）披露2025年年度报告，4月16日股价上涨1.6%
图解回盛生物年报：第四季度单季净利润同比增长137.25%
证券之星 · 04-16
图解回盛生物年报：第四季度单季净利润同比增长137.25%
回盛生物(300871.SZ)发布2025年度业绩，扭亏为盈至2.53亿元
智通财经 · 04-16
回盛生物(300871.SZ)发布2025年度业绩，扭亏为盈至2.53亿元
回盛生物（300871）披露延长2024年度向特定对象发行A股股票决议有效期公告，4月3日股价下跌5.66%
证券之星 · 04-03
回盛生物（300871）披露延长2024年度向特定对象发行A股股票决议有效期公告，4月3日股价下跌5.66%
回盛生物（300871）披露为全资孙公司提供1000万元担保公告，3月27日股价上涨3.25%
证券之星 · 03-27
回盛生物（300871）披露为全资孙公司提供1000万元担保公告，3月27日股价上涨3.25%
回盛生物（300871）披露2026年员工持股计划非交易过户完成公告，3月20日股价下跌3.3%
证券之星 · 03-20
回盛生物（300871）披露2026年员工持股计划非交易过户完成公告，3月20日股价下跌3.3%
回盛生物：公司在研发项目过程中也在运用AI技术以提高研发效率
证券之星 · 02-26
回盛生物：公司在研发项目过程中也在运用AI技术以提高研发效率
回盛生物：已预约2026年4月17日披露《2025年年度报告》
证券日报 · 02-26
回盛生物：已预约2026年4月17日披露《2025年年度报告》
回盛生物（300871）披露2026年第一次临时股东会决议公告，2月25日股价上涨0.44%
证券之星 · 02-25
回盛生物（300871）披露2026年第一次临时股东会决议公告，2月25日股价上涨0.44%
回盛生物（300871）披露2023年员工持股计划第二批股份锁定期届满提示性公告，2月5日股价下跌1.34%
证券之星 · 02-05
回盛生物（300871）披露2023年员工持股计划第二批股份锁定期届满提示性公告，2月5日股价下跌1.34%
回盛生物(300871.SZ)拟推2026年员工持股计划
智通财经 · 02-05
回盛生物(300871.SZ)拟推2026年员工持股计划
回盛生物最新公告：投资10亿元建设新疆合成生物学智造项目
证券之星 · 02-05
回盛生物最新公告：投资10亿元建设新疆合成生物学智造项目
最高4379%！6家A股公司净利同比预增超10倍
21世纪经济报道 · 01-28
最高4379%！6家A股公司净利同比预增超10倍
加载更多
公司概况
公司名称：
武汉回盛生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2020-08-24
主营业务：
武汉回盛生物科技股份有限公司的主营业务是兽用药品(包括化药制剂、原料药、中药制剂)、饲料及添加剂的研发、生产和销售。公司的主要产品是经济动物用重点产品、宠物用重点产品。公司是农业产业化国家重点龙头企业和全国农业农村信息化示范基地。截至2025年12月31日，公司已取得兽药批准文号317个。
发行价格：
33.61
{"stockData":{"symbol":"300871","market":"SZ","secType":"STK","nameCN":"回盛生物","latestPrice":21.52,"timestamp":1779951819000,"preClose":21.38,"halted":0,"volume":4485000,"delay":0,"changeRate":0.0065,"floatShares":202000000,"shares":202000000,"eps":1.4191,"marketStatus":"已收盘","change":0.14,"latestTime":"05-28 15:00:00","open":21.42,"high":21.74,"low":21.25,"amount":96309300,"amplitude":0.0229,"askPrice":21.52,"askSize":83,"bidPrice":21.51,"bidSize":15,"shortable":0,"etf":0,"ttmEps":1.4191,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":5,"adr":0,"adjPreClose":21.38,"symbolType":"stock","openAndCloseTimeList":[[1779931800000,1779939000000],[1779944400000,1779951600000]],"highLimit":23.52,"lowLimit":19.24,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":201784357,"isCdr":false,"pbRate":1.91,"roa":"--","peRate":15.164541,"roe":"3.51%","epsLYR":1.3349,"committee":-0.158824,"marketValue":4342000000,"turnoverRate":0.0222,"status":0,"floatMarketCap":4342000000},"requestUrl":"/m/hq/s/300871/","defaultTab":"news","newsList":[{"id":"2638531401","title":"回盛生物（300871）披露终止向特定对象发行股票审核决定公告，5月25日股价下跌3.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638531401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638531401?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:42","pubTimestamp":1779702141,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，回盛生物报收于22.0元，较前一交易日下跌3.38%，最新总市值为44.39亿元。公司近日披露《关于收到深圳证券交易所终止对公司申请向特定对象发行股票审核决定的公告》。公告显示，武汉回盛生物科技股份有限公司于2026年4月17日召开的2026年第二次临时股东会未审议通过延长2024年度向特定对象发行A股股票决议有效期及相关授权事项，导致该发行方案到期自动失效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500025166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638538575","title":"回盛生物不超2.5亿定增到期失效 保荐机构为中信建投","url":"https://stock-news.laohu8.com/highlight/detail?id=2638538575","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638538575?lang=zh_cn&edition=full","pubTime":"2026-05-25 14:54","pubTimestamp":1779692047,"startTime":"0","endTime":"0","summary":"中国经济网北京5月25日讯 回盛生物 22日发布关于收到深圳证券交易所终止对公司申请向特定对象发行股票审核决定的公告。 深圳证券交易所网站显示，回盛生物保荐机构为中信建投证券股份有限公司，保荐代表人为陈子晗、张兴华。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260525/32251394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300871","BK0239","601066","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637390529","title":"回盛生物最新公告：深交所终止对公司向特定对象发行股票审核","url":"https://stock-news.laohu8.com/highlight/detail?id=2637390529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637390529?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:27","pubTimestamp":1779442060,"startTime":"0","endTime":"0","summary":"回盛生物(300871.SZ)公告称，公司收到深圳证券交易所出具的《关于终止对武汉回盛生物科技股份有限公司申请向特定对象发行股票审核的决定》。因公司2024年度向特定对象发行股票方案已到期自动失效，深交所决定终止对公司申请向特定对象发行股票的审核。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200032227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630673023","title":"回盛生物(300871.SZ)发布一季度业绩，归母净利润7767.47万元，增长74.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630673023","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630673023?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:18","pubTimestamp":1777285112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，回盛生物(300871.SZ)发布2026年第一季度报告，该公司营业收入为4.58亿元，同比增长14.82%。归属于上市公司股东的净利润为7767.47万元，同比增长74.56%。归属于上市公司股东的扣除非经常性损益的净利润为7869.4万元，同比增长130.84%。基本每股收益为0.3839元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630361084","title":"回盛生物(300871)3月31日股东户数2.3万户，较上期增加15.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630361084","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630361084?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:32","pubTimestamp":1777282339,"startTime":"0","endTime":"0","summary":"证券之星消息，近日回盛生物披露，截至2026年3月31日公司股东户数为2.3万户，较12月31日增加3054.0户，增幅为15.32%。在动物保健行业个股中，回盛生物股东户数高于行业平均水平，截至3月31日，动物保健行业平均股东户数为2.26万户。根据统计，回盛生物2025年12月31日至2026年3月31日，主力资金净流出2.44亿元，游资资金净流出1.47亿元，散户资金净流入3.92亿元。期间龙虎榜该股共上榜1次，机构专用席位上榜1次。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700032149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630661653","title":"回盛生物涨5.81%，西南证券五日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2630661653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630661653?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:37","pubTimestamp":1777279055,"startTime":"0","endTime":"0","summary":"今日回盛生物涨5.81%，收盘报28.25元。2026年4月22日，西南证券研究员徐卿,赵磐发布了对回盛生物的研报《2025年年报点评：业绩创新高，原料药与新兴业务驱动高成长》，该研报对回盛生物给出“买入”评级。研报中预计2026-2028年EPS分别为1.65元、1.97元、2.47元，对应动态PE分别为17/14/11倍，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为23.86%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700029575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628228518","title":"黄果任国家药监局党组书记；全国四成统筹地区已完成上年度清算","url":"https://stock-news.laohu8.com/highlight/detail?id=2628228518","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628228518?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:10","pubTimestamp":1776384629,"startTime":"0","endTime":"0","summary":"政策动向全国四成统筹地区已提速完成上年度清算4月16日，国家医保局发布消息，截至2026年3月31日，全国30个省份（含新疆生产建设兵团）共154个统筹地区完成上年度清算，覆盖率达全国统筹区总数的39%，超额完成试点任务。其中，吉林白山、浙江宁波等43个非试点地区主动对标试点标准同步完成清算任务。山东、宁夏、北京、河北、海南、天津、河南等7个省（区、市）完成全省（区、市）清算。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173708185460.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173708185460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0889565916.HKD","LU0787776722.HKD","LU2552382215.SGD","BK4534","IE00BKDWB100.SGD","LU0882574055.USD","LU0122379950.USD","LU2361044865.SGD","BK4588","IE00BK4W5L77.USD","IE00BJJMRX11.SGD","BK0096","LU0385154629.USD","LU1223082196.USD","LU2213496289.HKD","IE0004445239.USD","LU2491050154.USD","LU2089984988.USD","LU0256863811.USD","LU2471134952.CNY","LU2237443465.HKD","688271","IE00BJJMRZ35.SGD","LU0133085943.USD","LU0320765992.SGD","LU1323610961.USD","ELIS","LU2462157665.USD","SG9999017495.SGD","LU0266013472.USD","LU0683600562.USD","LU2264538146.SGD","IE00B7KXQ091.USD","LU0353189763.USD","LU2168564149.EUR","LU0158827781.USD","LU2028103732.USD","LU0689472784.USD","LU1814569148.SGD","IE00BJJMRY28.SGD","LU1868836914.USD","LU2746668974.SGD","SG9999013999.USD","LU1989771016.USD","LU2361044949.HKD","IE00B2B36J28.USD","IE00BFSS8Q28.SGD","LU0234572021.USD","SG9999001176.USD","LU2896262040.SGD","BK4082","LU0256863902.USD","LU0114720955.EUR","LU1145028129.USD","LU0203202063.USD","BK0239","BK4585","LU0786609619.USD","IE00BJLML261.HKD","LU0094547139.USD","SG9999015978.USD","SGXZ57979304.SGD","LU2361045086.USD","LU2750360997.AUD","LU0456855351.SGD","LU1069344957.HKD","LU2236285917.USD","LU2746668461.USD","IE0004445015.USD","LU1720051017.SGD","LU1712237335.SGD","LU2324357040.USD","IE00BKPKM429.USD","LU0466842654.USD","LU2023250504.SGD","LU1551013425.SGD","LU2023250330.USD","LU0823434740.USD","SG9999014906.USD","SG9999015986.USD","BK4017","IE00B775H168.HKD","LU2237443895.HKD","IE0001KFT4U8.USD","LU2063271972.USD","LU2461242641.AUD","SG9999018857.SGD","LU0289739699.SGD","LU0640476718.USD","LU1267930730.SGD","LU0238689110.USD","LU2089283258.USD","SG9999018865.SGD","LU1223083913.SGD","LU2417539215.USD","LU0210536198.USD","IE00BFTCPJ56.SGD","LU2552382058.USD","LU1917777945.USD","LU2168564495.EUR","IE00BK4W5M84.HKD","LLII","BK4007","LU0323591593.USD","IE0009355771.USD","LLYX","LU2023251221.USD","IE00B4R5TH58.HKD","LU0964807845.USD","SGXZ81514606.USD","LU0097036916.USD","IE00B1BXHZ80.USD","LU1551013342.USD","IE0005OL40V9.USD","LU1127390331.HKD","LU2357305700.SGD","LU0106261372.USD","LU1093756168.USD","LU2360106947.USD","LU2087625088.SGD","LU0708995401.HKD","LU0820562030.AUD","LU0353189680.USD","LU2168563687.JPY","SGXZ31699556.SGD","LU1366192091.USD","LU0820561818.USD","LU2750360641.GBP","LU0225283273.USD","LU2471134796.USD","LU0079474960.USD","LU0823434583.USD","PYNKF","BK4516","BK4581","LU1629891620.HKD","LU1093756325.SGD","LU0471298777.SGD","LU2237438978.USD","LU0823416689.USD","LU0672654240.SGD","LU1232071149.USD","LU2552382132.HKD","LU2456880835.USD","LU1061106388.HKD","LU2271345857.HKD","LU1974910355.USD","LU1023059063.AUD","LU0882574139.USD","GB00BDT5M118.USD","LU1868836591.USD","LU0943347566.SGD","LU2211815571.USD","LU2491049909.HKD","SG9999014914.USD","LU0417517546.SGD","LU2168564065.EUR","LU2471134523.USD","LU2111349929.HKD","IE0002141913.USD","IE00BFSS7M15.SGD","LU2237443549.SGD","SG9999014898.SGD","IE00B1XK9C88.USD","SGXZ99366536.SGD","LU1623119135.USD","LU2112291526.USD","300871","LU1064131342.USD","000919","SG9999001176.SGD","BK4599","LU2168564222.USD","LU1983299246.USD","LU2265009873.SGD","LU0158827948.USD","LU0198837287.USD","LU2106854487.HKD","SG9999015945.SGD","LU1868837136.USD","SG9999015952.SGD","LU0820561909.HKD","BK4533","LU0316494557.USD","LU0471298694.HKD","IE00BJT1NW94.SGD","LU1035775433.USD","LU2089284900.SGD","LU2237443622.USD","IE00BWXC8680.SGD","LU2237443978.SGD","LU2108987350.USD","LU2471134879.HKD","LU1548497426.USD","LU2756315318.SGD","LLY","SGXZ51526630.SGD","LU1988902786.USD","LU1057294990.SGD","BK4168","LU1720051108.HKD","LU0109394709.USD","LU1804176565.USD","LU1868837300.USD","LU0354030511.USD","LU0096364046.USD","LU1868836757.USD","LU2491050071.SGD","LU0109391861.USD","ELIL","LU1280957306.USD","LU0432979614.USD","LU1291159041.SGD","IE00BN29S564.USD","IE00B4JS1V06.HKD","LU1223082519.USD","LU2468319806.SGD","BK0028","LU0354030438.USD","LU0006306889.USD","LLYZ","SG9999014880.SGD","LU2602419157.SGD","LU0061475181.USD","LU0203201768.USD","LU0320765059.SGD","LU2237443382.USD","LU2756315664.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627219955","title":"回盛生物（300871）披露2025年年度报告，4月16日股价上涨1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627219955","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627219955?lang=zh_cn&edition=full","pubTime":"2026-04-16 22:04","pubTimestamp":1776348261,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘，回盛生物报收于27.9元，较前一交易日上涨1.6%，最新总市值为56.3亿元。该股当日开盘27.25元，最高28.27元，最低27.01元，成交额达5.71亿元，换手率为10.19%。近日，回盛生物披露《2025年年度报告》。报告显示，公司实现营业收入1,681,248,059.49元，同比增长40.07%；归属于上市公司股东的净利润为253,155,975.55元，同比扭亏为盈，增幅达1,356.01%；扣除非经常性损益后的净利润为230,559,616.54元，同比增长1,519.83%。经营活动产生的现金流量净额为238,448,397.00元，同比增长447.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600043003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627929302","title":"图解回盛生物年报：第四季度单季净利润同比增长137.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627929302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627929302?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:07","pubTimestamp":1776330447,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物2025年年报显示，当年度公司主营收入16.81亿元，同比上升40.07%；归母净利润2.53亿元，同比上升1356.01%；扣非净利润2.31亿元，同比上升1519.83%；其中2025年第四季度，公司单季度主营收入4.22亿元，同比上升3.42%；单季度归母净利润6524.97万元，同比上升137.25%；单季度扣非净利润6471.26万元，同比上升300.48%；负债率27.33%，投资收益888.61万元，财务费用1291.71万元，毛利率30.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600030194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627260930","title":"回盛生物(300871.SZ)发布2025年度业绩，扭亏为盈至2.53亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627260930","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627260930?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:01","pubTimestamp":1776326503,"startTime":"0","endTime":"0","summary":"智通财经APP讯，回盛生物(300871.SZ)发布2025年年度报告，该公司营业收入为16.81亿元，同比增长40.07%。归属于上市公司股东的净利润为2.53亿元。归属于上市公司股东的扣除非经常性损益的净利润为2.31亿元。基本每股收益为1.3349元。此外，拟向全体股东每10股派发现金红利2.00元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651410","title":"回盛生物（300871）披露延长2024年度向特定对象发行A股股票决议有效期公告，4月3日股价下跌5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651410","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624651410?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:21","pubTimestamp":1775211675,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，回盛生物报收于24.98元，较前一交易日下跌5.66%，最新总市值为50.41亿元。公司于近日披露《关于延长公司2024年度向特定对象发行A股股票股东会决议有效期及相关授权有效期的公告》。原有效期至2026年4月18日，现拟延长12个月至2027年4月17日。本次延长事项尚需提交公司2026年第二次临时股东大会审议，关联股东需回避表决。除有效期延长外，本次发行方案其他内容保持不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239","399300","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820014","title":"回盛生物（300871）披露为全资孙公司提供1000万元担保公告，3月27日股价上涨3.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820014","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622820014?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:21","pubTimestamp":1774621281,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，回盛生物报收于23.83元，较前一交易日上涨3.25%，最新总市值为48.22亿元。本次担保金额在公司已审批的50,000万元担保额度范围内，无需另行提交董事会或股东会审议。截至2025年9月30日，其资产总额为8,322.08万元，净资产4,737.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700049928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620323732","title":"回盛生物（300871）披露2026年员工持股计划非交易过户完成公告，3月20日股价下跌3.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620323732","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620323732?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:19","pubTimestamp":1774016360,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，回盛生物报收于24.05元，较前一交易日下跌3.3%，最新总市值为48.66亿元。该股当日开盘24.89元，最高25.17元，最低24.02元，成交额达1.82亿元，换手率为3.69%。公告显示，武汉回盛生物科技股份有限公司已完成2026年员工持股计划非交易过户。本次员工持股计划股票来源为公司回购专用账户中的A股普通股，共205,400股，占公司总股本的0.10%，过户价格为15.00元/股。公司已开立员工持股计划专用证券账户，相关股份已过户并取得证券过户登记确认书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614304129","title":"回盛生物：公司在研发项目过程中也在运用AI技术以提高研发效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2614304129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614304129?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:53","pubTimestamp":1772110380,"startTime":"0","endTime":"0","summary":"公司密切关注AI技术在兽药行业的发展与应用，将AI等先进数字技术融入公司研发、生产、经营管理等方面。目前，公司在研发项目过程中，也在运用AI技术以提高研发效率，但相关研究短期内不会对公司经营业绩产生直接影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600035446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614351045","title":"回盛生物：已预约2026年4月17日披露《2025年年度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2614351045","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614351045?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:10","pubTimestamp":1772104200,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n 证券日报网讯 2月26日，回盛生物在互动平台回答投资者提问时表示，公司严格按照定期报告披露格式指引的要求，编制和披露定期报告，确保信息披露的真实、准确、完整。公司已预约2026年4月17日披露《2025年年度报告》。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-26/doc-inhpcyyh4332516.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-26/doc-inhpcyyh4332516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300871","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614331430","title":"回盛生物（300871）披露2026年第一次临时股东会决议公告，2月25日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614331430","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614331430?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:25","pubTimestamp":1772029521,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，回盛生物报收于27.37元，较前一交易日上涨0.44%，最新总市值为55.38亿元。公司于2026年2月25日发布《2026年第一次临时股东会决议公告》。关联股东对关联交易议案回避表决。会议召集召开程序合法，决议有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609309810","title":"回盛生物（300871）披露2023年员工持股计划第二批股份锁定期届满提示性公告，2月5日股价下跌1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309810?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:10","pubTimestamp":1770300631,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于2023年员工持股计划第二批股份锁定期届满的提示性公告》。公告显示，武汉回盛生物科技股份有限公司2023年员工持股计划第二批股份锁定期于2026年2月5日届满，解锁日为2026年2月6日，可解锁比例为30%，对应股票数量490,635股，占公司当前总股本的0.24%。公司员工持股计划存续期为48个月，自2024年2月6日起计算，分三期解锁，每期分别解锁40%、30%、30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609372298","title":"回盛生物(300871.SZ)拟推2026年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2609372298","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609372298?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:18","pubTimestamp":1770293902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，回盛生物(300871.SZ)披露2026年员工持股计划(草案)，参与对象总人数不超过14人，拟筹集资金总额不超过人民币308.10万元，以“份”作为认购单位，每份份额为1.00元，员工持股计划的份数上限为308.10万份。员工持股计划股票来源为公司回购专用证券账户回购的回盛生物A股普通股股票。本计划经公司股东会审议通过后，将通过非交易过户等法律法规允许的方式受让公司回购专用证券账户所持有的公司股份。员工持股计划受让的股份总数不超过20.54万股，占员工持股计划草案公告日公司股本总额的0.10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300871","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609644372","title":"回盛生物最新公告：投资10亿元建设新疆合成生物学智造项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2609644372","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609644372?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:00","pubTimestamp":1770292845,"startTime":"0","endTime":"0","summary":"回盛生物(300871.SZ)公告称，公司于2月4日召开董事会，审议通过全资子公司新疆回盛投资建设新疆合成生物学智造项目，项目总投资10亿元，分三期建设。项目旨在满足市场需求，突破产能与效率瓶颈，实现技术升级和成本控制目标。项目符合西部地区鼓励类产业政策，可享受当地税收优惠，并满足绿色发展要求。项目存在市场、技术和国际贸易风险，公司将通过加强市场监测、加大研发投入和拓展海外渠道来应对。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500035808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606982777","title":"最高4379%！6家A股公司净利同比预增超10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2606982777","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606982777?lang=zh_cn&edition=full","pubTime":"2026-01-28 15:29","pubTimestamp":1769585351,"startTime":"0","endTime":"0","summary":"作为业绩预增榜首，宁波富邦在1月27日晚披露的业绩预告中表示，预计2025年度实现归属于母公司所有者的净利润为5000万元到7000万元，与上年同期相比，将增加4843.73万元到6843.73万元，同比将增长3099.59%到4379.43%。整体看，A股已发布业绩预告的公司中，2025年度净利同比预增超100%有253家，其中有123家扭亏、130家预增。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128153218a6b63e20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128153218a6b63e20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01772","300850","BK1509","SG9999006597.SGD","BK1129","SG9999003461.SGD","600867","BK1190","300871","BK1592","002553","BK1594","600768","601388"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780009845886,"stockEarnings":[{"period":"1week","weight":-0.0561},{"period":"1month","weight":-0.2082},{"period":"3month","weight":-0.2169},{"period":"6month","weight":0.0929},{"period":"1year","weight":-0.0725},{"period":"ytd","weight":0.0381}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0049},{"period":"3month","weight":-0.0154},{"period":"6month","weight":0.054},{"period":"1year","weight":0.2272},{"period":"ytd","weight":0.0327}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉回盛生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22983人(较上一季度增加15.32%)","perCapita":"8779股","listingDate":"2020-08-24","address":"湖北省武汉市东西湖区新沟街道办事处油纱路52号","registeredCapital":"20178万元","survey":" 武汉回盛生物科技股份有限公司的主营业务是兽用药品(包括化药制剂、原料药、中药制剂)、饲料及添加剂的研发、生产和销售。公司的主要产品是经济动物用重点产品、宠物用重点产品。公司是农业产业化国家重点龙头企业和全国农业农村信息化示范基地。截至2025年12月31日，公司已取得兽药批准文号317个。","listedPrice":33.61},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"回盛生物(300871)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供回盛生物(300871)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"回盛生物,300871,回盛生物股票,回盛生物股票老虎,回盛生物股票老虎国际,回盛生物行情,回盛生物股票行情,回盛生物股价,回盛生物股市,回盛生物股票价格,回盛生物股票交易,回盛生物股票购买,回盛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"回盛生物(300871)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供回盛生物(300871)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}